Human PlGF Antibody

R&D Systems, part of Bio-Techne | Catalog # MAB11197

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
MAB11197-100
MAB11197-SP
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Species Reactivity

Human

Applications

Neutralization

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG2A Clone # 1038863

View all PlGF Antibodies »

Product Specifications

Immunogen

E. coli-derived human PlGF
Ala21-Arg149
Accession # P49763

Specificity

Detects human PIG-1,2,3 and 4 in direct ELISAs.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG2A

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Scientific Data Images for Human PlGF Antibody

VEGFR1/Flt-1 Binding to PlGF is Blocked by Human PlGF Antibody

In a functional ELISA, 0.150-1.80 µg/mL of this antibody will block 50% of the binding of 100 ng/mL Recombinant Human VEGFR1/Flt-1 Fc Chimera, aa 27-328 (3516-FL) to Recombinant Human PlGF (264-PGB) immobilized at 0.5 μg/mL (100 µL/well)

Applications for Human PlGF Antibody

Application
Recommended Usage

Neutralization

In a functional ELISA binding assay, 0.150-1.80 ug/mL of this antibody will block the binding of 100 ng/mL of recombinant human VEGFR1/Flt-1 Fc Chimera (Catalog # 3516-FL) to immobilized recombinant human PLGF (Catalog # 264-PGB) coat at 0.5 ug/mL (100 uL/well).

Formulation, Preparation, and Storage

Purification

Protein A or G purified from hybridoma culture supernatant

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Reconstitution Buffer Available:
Size / Price
Qty

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: PlGF

Placenta Growth Factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines (1, 2). Alternative splicing results in at least three human mature PlGF forms containing 131 (PlGF-1), 152 (PlGF-2), and 203 (PlGF-3) amino acids (aa) respectively (1, 2). Only PlGF-2 contains a highly basic heparin-binding 21 aa insert at the C-terminus (1). Human PlGF-1 shares 56%, 55%, 74% and 95% aa identity with the comparable isoform of mouse, rat, canine, and equine PlGF, respectively. PlGF is mainly found as variably glycosylated, secreted, 55-60 kDa disulfide linked homodimers (3). Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes, and some endothelial cells (1, 4-6). Circulating PlGF increases during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia (7). However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia (8). PlGF binds and signals through VEGF R1/Flt-1 but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2-mediated angiogenesis (1, 4, 8, 9). However, PlGF (especially PlGF-1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2 (3, 4). PlGF-2, but not PLGF-1, shows heparin-dependent binding of Neuropilin (Npn)-1 and Npn-2 (10, 11). PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound, bone fracture, and cardiac repair, but also contribute to inflammation in active sickle cell disease and atherosclerosis (5, 6, 8, 12-15). PlGF can also inhibit TIMP3 expression in the spleen, leading to immune triggering of hypertension (16).

References

  1. Hauser, S. and H.A. Weich (1993) Growth Factors 9:259.
  2. Maglione, D. et al. (1993) Oncogene 8:925.
  3. Eriksson, A. et al. (2002) Cancer Cell 1:99.
  4. Ribatti, D. (2008) Angiogenesis 11:215.
  5. Oura, H. et al. (2003) Blood 101:560.
  6. Roncal, C. et al. (2010) Cardiovasc. Res. 86:29.
  7. Levine, R.J. et al. (2004) N. Engl. J. Med. 350:672.
  8. Carmeliet, P. et al. (2001) Nat. Med. 7:575.
  9. Autiero, M. et al. (2003) Nat. Med. 9:936.
  10. Migdal, M. et al. (1998) J. Biol. Chem. 273:22272.
  11. Cheng, L. et al. (2004) J. Biol. Chem. 279:30654.
  12. Perelman, N. et al. (2003) Blood 102:1506.
  13. Cianfarani, F. et al. (2006) Am. J. Pathol. 169:1167.
  14. Maes, C. et al. (2006) J. Clin. Invest. 116:1230.
  15. Iwasaki, H. et al. (2011) PLoS One 6:e24872.
  16. Carnevale, D. et al. (2014) Immunity 41:737.

Long Name

Placenta Growth Factor

Alternate Names

PGF, PGFL

Entrez Gene IDs

5228 (Human); 18654 (Mouse)

Gene Symbol

PGF

UniProt

P49763

Additional PlGF Products

Product Documents for Human PlGF Antibody

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Human PlGF Antibody

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.